Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) stock rose 2% following the company’s presentation of new preclinical data for its TNX-801 vaccine candidate at the Vaccine Congress 2025 in Vienna.
The biopharmaceutical company revealed that its recombinant horsepox-derived vaccine showed potential to deliver durable immunity while remaining highly attenuated compared to earlier orthopox vaccines. A key finding highlighted that subcutaneous administration of TNX-801 provides equivalent protection to percutaneous administration, which the company plans to prioritize in development.
According to preclinical studies, TNX-801 demonstrated significantly lower replication in primary human dermal cells compared to licensed vaccinia strains, replicating 27 to 119-fold less. In interferon receptor knockout mice, it showed up to 100,000-fold less virulence than legacy vaccines.
The studies also revealed that a single dose of TNX-801 produced strong binding and neutralizing antibody responses across multiple animal models, including immunocompromised animals. All vaccinated macaques survived lethal Clade I mpox challenge without lesions, while rabbit models remained fully protected for 14 months.
TNX-801 is being developed as a potential tool for containing mpox outbreaks and as a preparedness measure against potential smallpox reintroduction. The World Health Organization and Centers for Disease Control and Prevention continue to classify mpox as an ongoing public health concern.
The company believes a single-dose vaccine with TNX-801’s profile could streamline outbreak response by eliminating the need for multi-visit immunization schedules currently required by approved vaccines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.